TIFAB: A Potential Drug Target and Biomarker for Interactions between Traf and FHA Proteins

Target Name: TIFAB

NCBI ID: G497189

TIFAB

TIFAB: A Potential Drug Target and Biomarker for Interactions between Traf and FHA Proteins

Introduction

Proteins play a crucial role in various biological processes, and their interactions with other proteins are essential for their function. One such interaction is the interaction between the protein TIFAB and the protein FHA, which has been implicated in various diseases. TIFAB and FHA interactions have been observed, and they have been proposed as potential drug targets or biomarkers. In this article, we will explore the TIFAB protein and its interaction with FHA, as well as its potential as a drug target or biomarker.

TIFAB: Structural and Functional Characterization

TIFAB (TRAF-interacting protein with FHA domain-containing protein B) is a protein that has been identified through various studies, including X-ray crystallography and bioinformatics analysis. TIFAB is a 21-kDa protein that contains a N-terminal FHA domain, a TAF (T-takeover helix) domain, and a C-terminal TIF (TI false domain) domain. The FHA domain is a key region that interacts with TIFAB, and the TIFAB protein is able to interact with FHA in a similar way as a chaperone protein.

Functional Analysis of TIFAB

TIFAB has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. TIFAB has also been shown to interact with various proteins, including FHA, which is a protein that has been implicated in various diseases, including cancer.

In addition to its interaction with FHA, TIFAB has also been shown to interact with other proteins, including the protein ZNF2 (Zeb1/2). ZNF2 is a transcription factor that has been shown to play a role in various cellular processes, including cell growth , differentiation, and survival. TIFAB has also been shown to interact with ZNF2 in a similar way as it interacts with FHA.

Potential Drug Target or Biomarker

TIFAB's interaction with FHA and its other interactions with proteins have led to its potential as a drug target or biomarker. Studies have shown that TIFAB can interact with small molecules, including inhibitors of the FHA-TIFAB interaction, which may have potential as drug candidates.

In addition to its potential as a drug target, TIFAB has also been shown to be a biomarker for various diseases, including cancer. TIFAB has been shown to be expressed in various tissues and has been used as a marker for cancer, including breast and ovarian cancers.

Conclusion

TIFAB is a protein that has been identified through various studies and has been shown to interact with FHA and other proteins. Its potential as a drug target or biomarker has been demonstrated through various studies, including its interaction with small molecules and its expression in various tissues . Further research is needed to fully understand the role of TIFAB in various biological processes and to develop safe and effective drugs or biomarkers based on its interaction with FHA.

Protein Name: TIFA Inhibitor

Functions: Inhibits TIFA-mediated TRAF6 activation possibly by inducing a conformational change in TIFA

The "TIFAB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIFAB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets